Expression, regulation and physiological roles of the five Rsm proteins in Pseudomonas syringae pv. tomato DC3000.

Proteins belonging to the RsmA (regulator of secondary metabolism)/CsrA (carbon storage regulator) family are small RNA-binding proteins that play crucial roles post-transcriptionally regulating gene expression in many Gram-negative and some Gram-positive bacteria. Although most of the bacteria studied have a single RsmA/CsrA gene, Pseudomonas syringae pv. tomato (Pto) DC3000 encodes five Rsm proteins: RsmA/CsrA2, RsmC/CsrA1, RsmD/CsrA4, RsmE/CsrA3, and RsmH/CsrA5.

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Background: Immune checkpoint inhibitors (ICI) have changed the therapeutic landscape of many solid tumors. Modulation of the intestinal microbiota by antibiotics (Abx) has been suggested to impact on ICI outcomes.

Methods: Retrospective analysis of 475 patients with advanced solid tumors treated with ICI from 2015 to 2022.

Nuclear localization of Pretaporter in third-instar larvae salivary gland and its deficiency-associated nuclear phenotype.

The protein Pretaporter, is thought to reside in the endoplasmic reticulum and relocate to the plasma membrane during apoptosis. However, very little is known about its subcellular distribution in different cell types and conditions. Here, we present the first report of Pretaporter´s subcellular distribution in the salivary gland cells of third-instar larvae, finding it enriched in cell membranes, apical granules, and unexpectedly within cell nuclei.

Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

Previous studies have suggested a negative impact of steroids on the efficacy of immune checkpoint inhibitors (ICI), but how this effect is modulated by the dosage and time of administration is yet to be clarified. We have performed a retrospective analysis of 475 patients with advanced solid tumors treated with ICI as monotherapy from 2015 to 2022. Data regarding immune-related adverse events (irAEs) and clinical outcomes were collected.